Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.